APSR2026-512

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP07-004
P54
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1207568-46904-APSR26poster_433856.pdf
Format: PDF Only
03. Clinical Allergy and Immunology
5

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Tomoyuki Ikeuchi * National Hospital Organization (NHO) Yonago Medical Center Department of Respiratory Medicine Yonago Japan
Mitsuhiro Yamamoto - National Hospital Organization (NHO) Yonago Medical Center Department of Respiratory Medicine Yonago Japan
Hirokazu Toge - National Hospital Organization (NHO) Yonago Medical Center Department of Respiratory Medicine Yonago Japan
Naoto Burioka - National Hospital Organization (NHO) Yonago Medical Center Department of Respiratory Medicine Yonago Japan
Akira Yamasaki - Faculty of Medicine, Tottori University Division of Respiratory Medicine and Rheumatology Yonago Japan
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Tomoyuki
Ikeuchi
ike10moy@gmail.com
+819094616346
51-60
Japan
Case Report
Successful inhaled sargramostim therapy in a 91-year-old patient with autoimmune pulmonary alveolar proteinosis associated with rheumatoid arthritis
Maximum 25 words
Abstract Content
 
 
 
 
Autoimmune pulmonary alveolar proteinosis (aPAP) and rheumatoid arthritis (RA) represent contradictory pathological conditions: aPAP is characterized by insufficient granulocyte-macrophage colony-stimulating factor (GM-CSF) activity due to neutralizing autoantibodies, whereas RA is characterized by excessive GM-CSF as an inflammatory cytokine. Consequently, the coexistence of both diseases is extremely rare (Hashimoto M et al, Annals of the Japanese Respiratory Society. 2020, 9, 477-81).
A 91-year-old woman with a long-standing diagnosis of RA, achieving disease stabilization with salazosulfapyridine (SASP), presented with bilateral ground-glass opacities and a crazy-paving pattern on chest computed tomography. She was diagnosed with aPAP based on positive serum anti-GM-CSF antibodies and periodic acid-Schiff-positive alveolar fluid on transbronchial lung biopsy. She was treated with inhaled sargramostim (GM-CSF) therapy (Tazawa R et al, N Engl J Med. 2019, 381, 923-32), which was well tolerated without significant adverse events despite her advanced age of 91 years. Following the completion of 12 scheduled treatment courses, chest imaging demonstrated marked radiological improvement.
A review of previously reported cases revealed that four out of five patients with concurrent aPAP and RA, including the present case, were receiving SASP treatment. We previously reported that aPAP in this setting may develop through dual suppression of GM-CSF (Ikeuchi T et al, Cureus 2025, 17(12), e99760): drug-induced inhibition of alveolar GM-CSF activity by SASP, combined with acquired anti-GM-CSF autoantibody production. In the present report, we provide a detailed description of the clinical course following inhaled sargramostim therapy. Notably, the treatment was well tolerated and yielded radiological improvement after 12 courses, suggesting that inhaled sargramostim may represent a safe and effective therapeutic option even in elderly patients. Clinicians should consider PAP in the differential diagnosis when respiratory symptoms or pulmonary abnormalities develop in patients with RA receiving SASP.
 
 
Yes
No
 
JPG or JPEG or PNG format ONLY
autoimmune pulmonary alveolar proteinosis, sargramostim therapy, rheumatoid arthritis
maximum 3 keywords and no abbreviations, separated by commas
 
287